InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: djohn post# 22115

Friday, 08/28/2015 5:00:36 PM

Friday, August 28, 2015 5:00:36 PM

Post# of 345700

What you don't seem to get is that if Bavi works managements options will be worth millions and so will my shares. That's why we are all here right??? Or is it to have WINE with your cheese?



I agree djohn, we are not here to whine nor complain but dig deeper and see what is coming before all others.

I hope you read the new patent and understand that PS Targeting is required and that is what they are closing in on.

---------------------

requiring both advance knowledge of a particular exosome surface marker to be exploited in the antibody binding,

--------------------

look for those words in the patent and they are talking about PS Targeting and anyone, anyone and absolutely anyone heading down deeper on this road "MUST" target PS

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116591450

---------------------

Alan Schroit has been around for a while and worked with the late Dr. Thorpe since the beginning and its clearly in front of you that flipped PS is the most global biomarker and now they are breaking it down to the many lipid proteins that makes up flipped PS so I think we can forget about exec salaries for now. They will be making a hell of a lot more of a rising PPHM once the flood gates are allowed to open.

----------------------

A novel "salting-out" procedure for the isolation of tumor-derived exosomes.

http://www.ncbi.nlm.nih.gov/pubmed/24735771

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News